Home › Alzheimer's Disease › NCT07496918

Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)

Pilot Study to Evaluate Feasibility of Sensory Stimulation With Gamma Frequency Entrainment

Who can join

Ages 18 to 100 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Have adequate visual and auditory acuity for visual and auditory stimulation to allow for neuropsychological testing.
* Be able to comply with neuropsychological testing and other study procedures in opinion of site PI.

Exclusion Criteria: Participants will be screened for the following exclusion criteria including if they

* History of seizure or medical diagnosis of epilepsy.
* Have MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
* Under the discretion of the site investigator, the site investigator feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.

About the study

Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.

What is being tested

• GENUS (device)
• Tactile GENUS (device)

Sponsor: Massachusetts Institute of Technology · Participants: 150 · Started: Feb 20, 2018

Contact the study team

• gamma wave · Phone: 617-258-7723
• Ana Trisini Lipsanopoulos, BS · Phone: 617-258-7723

Official record on ClinicalTrials.gov — NCT07496918

Locations in the U.S.

Conditions

• Alzheimer's Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.